A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice

Inclusion Criteria:

• Signed consent obtained before any study-related activities (study-relatedactivities are any procedure related to recording of data according to the protocol)

• Diagnosed with type 2 diabetes mellitus

• The decision to initiate treatment with commercially available oral semaglutide hasbeen made by the patient/Legally Acceptable Representative (LAR) and the treatingphysician based on local label before and independently from the decision to includethe patient in this study

• Male or female, age above or equal to 18 years at the time of signing informedconsent

• Available HbA1c value less than or equal to 90 days prior to the 'Informed Consentand Treatment Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation visit' (V1) if in line with localclinical practice

• Treatment naive to injectable glucose-lowering drug(s). An exception is short-terminsulin treatment for acute illness for a total of less than 14 days

Exclusion Criteria:

• Previous participation in this study. Participation is defined as having giveninformed consent in this study

• Treatment with any investigational drug within 30 days prior to enrolment into thestudy

• Mental incapacity, unwillingness or language barriers precluding adequateunderstanding or cooperation